Radnostix Inc. reported a wider third-quarter loss after a sharp decline in cobalt sales, as stronger theranostics demand failed to offset delayed contracts and a supply interruption affecting its results.
Revenue fell 22% to $2.57 million in the three months ended Sept. 30, from $3.28 million a year earlier. The net loss widened to $842,242 from $203,601, the company reported Nov. 16. For the first nine months of 2026, revenue fell to $7.62 million from $10.17 million, while the net loss reached $3.07 million, compared with $477,080.
Quarterly cobalt sales dropped to $90,680 from $766,682. Radnostix said large contracts have been delayed while amendments to its registered sealed-source devices await action by the U.S. Nuclear Regulatory Commission (NRC).
Calibration and reference product sales declined to $737,222 from $961,093. The company estimated that an interruption in cobalt-57 supply reduced third-quarter sales by about $250,000. It also reported a cobalt-57 shortage in 2024 that was followed by catch-up sales in 2025.
Theranostics sales rose 15% to $1.71 million for the quarter. Radnostix said customer volumes recovered in July after two voluntary recalls earlier in 2026, though sales for the first nine months remained 19% below the year-earlier period at $4.18 million.
Cash and equivalents stood at $711,288 on Sept. 30, down from $1.70 million at the end of 2025. Radnostix entered a $1 million revolving credit agreement in October. It has also agreed to sell assets tied to its fluorine business and a planned depleted uranium facility to HALEU Energy Fuel Inc., a subsidiary of Nano Nuclear Energy Inc.
The conditional sale is valued at $13.5 million, including $9.5 million in cash and $4 million in restricted Nano Nuclear shares. Radnostix said $500,000 was released to it from escrow in October. Up to an additional $9 million in cash, less any payments to release liens, is due at closing. Conditions include NRC approval of a license transfer and the buyer obtaining rights to the project site.
Radnostix also said it submitted a Type II Drug Master File to the U.S. Food and Drug Administration (FDA) in October for Sodium Iodide I-131 active pharmaceutical ingredient to support a customer’s drug application. FDA does not approve Drug Master Files separately; it assesses their contents when reviewing applications that cite them.
Radnostix expects to execute the delayed cobalt contracts in the first quarter of 2027, subject to the NRC amendments.



